Scarica l'app Stockscreener
1.51
4.86%
0.07
Dopo l'orario di chiusura:
1.52
0.01
+0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.44
Aprire:
$1.5
Volume 24 ore:
10.11M
Relative Volume:
1.21
Capitalizzazione di mercato:
$511.16M
Reddito:
$4.41M
Utile/perdita netta:
$-67.85M
Rapporto P/E:
-6.6873
EPS:
-0.2258
Flusso di cassa netto:
$-57.15M
1 W Prestazione:
-16.11%
1M Prestazione:
-18.82%
6M Prestazione:
+11.03%
1 anno Prestazione:
+119.03%
Intervallo 1D:
$1.445
$1.52
Intervallo di 1 settimana:
$1.38
$1.90
Portata 52W:
$0.64
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.51 | 511.16M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Iniziato | Canaccord Genuity | Buy |
| 2026-03-11 | Iniziato | Oppenheimer | Outperform |
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Pipeline Proof Remains the Prize - AD HOC NEWS
Ocugen stock dips as Q1 losses widen - MSN
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed? - Yahoo! Finance Canada
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (OCGN) Upgraded to Buy: Here's Why - Yahoo Finance
Ocugen’s Convertible Lifeline Fuels a Three-Pronged Gene Therapy Sprint - AD HOC NEWS
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
symbol__ Stock Quote Price and Forecast - CNN
Ocugen (NASDAQ: OCGN) posts larger Q1 2026 loss and raises $115M in convertible notes - Stock Titan
Number of shareholders of Ocugen Inc – LSX:A2PSZH - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Raises Capital Through Convertible Senior Notes Offering - TipRanks
Ocugen (NASDAQ: OCGN) sells $115M 2034 convertibles, retires Avenue loan - Stock Titan
Chardan Capital Initiates Ocugen(OCGN.US) With Buy Rating, Announces Target Price $7 - Moomoo
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Investors Want Pipeline Proof - AD HOC NEWS
Ocugen’s $115 Million Convertible Bet Raises the Stakes for a Trio of Gene Therapy Trials - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook - The Globe and Mail
Full Transcript: Ocugen Q1 2026 Earnings Call - Sahm
Ocugen’s Convertible Debt Deal Funds a Pipeline Push, but Investors Balk at Dilution Risk - AD HOC NEWS
Ocugen Q1 2026 Earnings Call Transcript - MarketBeat
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Prices $115 Million Convertible Senior Notes Offering - Moomoo
Ocugen outlines plan for 3 BLAs by 2028 as it expects cash runway into 2028 - MSN
Ocugen Q1 Earnings Call Highlights - Yahoo Finance
Ocugen stock plunges after gene therapy company announces $115M debt sale - The Business Journals
OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes - Traders Union
Ocugen prices $115 million convertible notes offering at 6.75% By Investing.com - Investing.com South Africa
Ocugen reports Q1 results, raises $115M in convertible notes By Investing.com - Investing.com Australia
Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway - TipRanks
Ocugen reports Q1 results, raises $115M in convertible notes - Investing.com UK
Ocugen Provides Business Update with First Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen (NASDAQ: OCGN) prices $115M 2034 convertible notes deal - Stock Titan
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen Down Over 19%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk - Moomoo
Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue By Investing.com - Investing.com Nigeria
Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue - Investing.com
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Ocugen stock tumbles 17% after convertible notes offering - Investing.com
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 - ChartMill
Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes - marketscreener.com
OCUGEN ($OCGN) Releases Q1 2026 Earnings - Quiver Quantitative
Ocugen: Q1 Earnings Snapshot - Barchart.com
OCGN: Strong clinical progress and extended cash runway position the pipeline for key regulatory milestones - TradingView
Ocugen says two blindness gene therapy trials are fully enrolled - Stock Titan
Ocugen prices $115 million convertible notes offering at 6.75% - Investing.com
Ocugen, Inc. Announces Pricing Of $115 Million Of 6.75% Convertible Senior Notes - TradingView
Q1 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen, Inc. Announces Pricing of $115 Million Convertible Senior Notes Offering - Quiver Quantitative
Ocugen's $115M note deal sends $32.7M to repay Avenue loan - Stock Titan
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.97%
3.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):